Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | PIK3CA K111N |
Therapy | GSK2334470 + Miransertib |
Indication/Tumor Type | breast cancer |
Response Type | sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
PIK3CA K111N | breast cancer | sensitive | GSK2334470 + Miransertib | Preclinical - Cell culture | Actionable | In a preclinical study, GSK2334470 and Miransertib (ARQ092) combination treatment increased cell death compared to Miransertib (ARQ092) alone in a breast cancer cell line harboring PIK3CA K111N in culture (PMID: 32439931). | 32439931 |
PubMed Id | Reference Title | Details |
---|---|---|
(32439931) | A systematic molecular and pharmacologic evaluation of AKT inhibitors reveals new insight into their biological activity. | Full reference... |